The All-India Institute of Medical Sciences (AIIMS) in Delhi will start recruitment for clinical trials from today onwards for the children who are in the age group of 6-12 years according to agency reports. It further said that clinical trials of children of the 2-6 age group will start after this trial.
The screening of children for the trial of single-dose Covaxin was earlier dome by India’s first indigenously developed COVID-19 vaccine among the age group between 2 and 18 started at the AIIMS in New Delhi on 7 June and is over.
AIIMS Patna has already started their trial on children to see if the Bharat Biotech jab is suitable for children, hence the participants would be given the vaccine after their screening report comes.
Last week the government warned that even though COVID-19 has not taken a serious turn among children till now, its impact can increase among them if there is a change in virus behaviour or epidemiology dynamics, and said preparations are being strengthened to deal with any situation like this.
Covaxin is being used on adults in India’s ongoing coronavirus vaccination drive. Meanwhile India’s drug regulator has granted permission for conducting the Phase 2/3 clinical trial of Covaxin in the age group 2 to 18 years on May 12.
NITI Aayog Member (Health) V.K. Paul had said at a press conference that a national expert group has been formed to review coronavirus infections in children and approach the pandemic in a transformed way to strengthen the country’s preparedness.
The signs which were not available for four-five months before has been examined by the group.
“While we have been systematically reviewing scientific developments in this area, the group has been formed to take an updated view of the situation,” Mr. Paul said.
It has also considered available data, clinical profile, the country’s experience, disease dynamics, nature of the virus and the pandemic and has come up with guidelines, which will be publicly released soon.
When asked if the Pfizer vaccine comes to India will it be considered for children between the age of 12 and 15 years as being approved by the U.K, Mr. Paul had said that the country has its own vaccines which are being readied for children.
“Child cohort is not a small cohort. My rough guess is that if it is between 12 to 18 years, this itself is about 13 to 14 crore population and for which we will need about 25-26 crore doses. “We cannot have some people getting and others not getting. So we will have to take this into account when we strategise and make a decision based on how many doses of which vaccines are available,” he said.
He further shared that Zydus Cadila’s vaccine is already being tested in children.